2016 American Transplant Congress
Rituximab Induction in Cardiac Transplantation Is Associated with Accelerated Coronary Artery Vasculopathy: CTOT11.
On Behalf of the CTOT11 Consortium, Brigham & Women's Hospital, Boston, MA.
PurposeThe NIH-funded study CTOT11: Prevention of Cardiac Allograft Vasculopathy Using Rituximab (RIT) Therapy in Cardiac Transplantation, was a randomized clinical trial in non-sensitized primary heart…2016 American Transplant Congress
Learning from Cancer: Using D-Lactate for Therapeutic Immunosuppression.
Accumulation of lactic acid in the tumor microenvironment contributes to local immunosuppressive conditions that weaken anti-tumor immunity. Lactic acid exists as L- and D- optical…2016 American Transplant Congress
Long Term Outcome of Kidney Transplant Recipients Treated with Everolimus: Final 5-Years Results from the Certic Observational Study.
Everolimus is associated with long-term benefits, such as preserving renal function and reducing the incidence of infections, malignancies and major cardiovascular events (MACE). The Certic…2016 American Transplant Congress
Prospective Randomized Study of a Steroid Free, Low Dose Tacrolimus with Everolimus Regimen in Kidney Transplant.
Northwestern University, Chicago, IL; University of Virginia, Chicago, IL.
Calcineurin inhibitors (CNI) serve as the cornerstone of immunosuppression (IS) after kidney transplant. However chronic CNI nephrotoxicity has been implicated in allograft dysfunction. We hypothesize…2016 American Transplant Congress
Gene Expression Profiling Score and the Risk of Infection in Heart Transplant Recipients.
Purpose: This study assessed the association of gene expression profiling (GEP, AlloMap®) score with infections in heart transplant recipients (HTR). Although a GEP score below…2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…2016 American Transplant Congress
Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.
BackgroundComplications caused by long-term immunosuppression remain a major concern for transplant patients. To optimize controlled and accurate dosing, we investigated an innovative drug delivery method…2016 American Transplant Congress
Early Tacrolimus Exposure in Patients Treated De Novo with Once-Daily Tacrolimus After Liver Transplantation: Relationship with Acute Rejection and Long-Term Outcome.
Liver Transplantation Unit, Cruces University Hospital, Bilbao, Vizcaya, Spain.
AIM: The aim of our study was to define the possible influence of early tacrolimus exposure on long-term outcomes in patients treated with de novo…2016 American Transplant Congress
Costimulation Blockade by Anti CD40 Antibody Prevents Humoral and Cellular Rejection of Heterotopic Pig Cardiac Xenograft.
1CSRP/NHLBI, NIH, Bethesda, MD; 2DVR/ORS, NIH, Bethesda, MD; 3Revivicor Inc., Blacksburg, VA.
BackgroundXenotransplantation (XTx) involves the participation of innate immune system with natural antibody producing B cells, NK cells, macrophages and complement as well as adaptive immune…2016 American Transplant Congress
Early Post-Transplant Immunosuppression (IS) Withdrawal – Final Outcomes of the ITN030ST AWISH Study.
ITN030ST is a prospective randomized trial designed to determine the clinical benefit of early IS withdrawal in adult liver transplant (LT) recipients. Recipients did not…
- « Previous Page
- 1
- …
- 101
- 102
- 103
- 104
- 105
- …
- 138
- Next Page »